Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis
| العنوان: | Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis |
|---|---|
| المؤلفون: | F. Moreno, José L Justicia, Begoña Navarro, Albert Roger, Antonio Parra, Diego Gutiérrez, Victoria Moreno, Antonio Valero, Ramón Lleonart, Alfons Malet, Belén Hinojosa |
| المصدر: | Immunotherapy r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname Dipòsit Digital de la UB Universidad de Barcelona |
| بيانات النشر: | Future Medicine Ltd., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_treatment, Dermatophagoides pteronyssinus, subcutaneous allergen immunotherapy, 0302 clinical medicine, Subcutaneous immunotherapy, Clinical endpoint, Àcars, Immunology and Allergy, Prospective Studies, 030212 general & internal medicine, Rinitis, Rhinitis, Mites, biology, Pyroglyphidae, Middle Aged, Treatment Outcome, Oncology, Tolerability, Female, Novobiocin, After treatment, house dust mites, Adult, safety, medicine.medical_specialty, Adolescent, Injections, Subcutaneous, Immunology, effectiveness, Young Adult, 03 medical and health sciences, Adjuvants, Immunologic, Internal medicine, medicine, Mite, Animals, Humans, In patient, Antigens, Dermatophagoides, Adverse effect, Aged, allergic rhinitis, business.industry, Immunotherapy, biology.organism_classification, Rhinitis, Allergic, 030228 respiratory system, Desensitization, Immunologic, adjuvants, real-life clinical practice, Tyrosine, business |
| الوصف: | Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting. |
| وصف الملف: | application/pdf |
| تدمد: | 1750-7448 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1710503f1a390d2e1b48d8873ddffc8fTest https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=3990Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....1710503f1a390d2e1b48d8873ddffc8f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17507448 |
|---|